Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ.

Ding L, Su Y, Fassl A, Hinohara K, Qiu X, Harper NW, Huh SJ, Bloushtain-Qimron N, Jovanović B, Ekram M, Zi X, Hines WC, Alečković M, Gil Del Alcazar C, Caulfield RJ, Bonal DM, Nguyen QD, Merino VF, Choudhury S, Ethington G, Panos L, Grant M, Herlihy W, Au A, Rosson GD, Argani P, Richardson AL, Dillon D, Allred DC, Babski K, Kim EMH, McDonnell CH 3rd, Wagner J, Rowberry R, Bobolis K, Kleer CG, Hwang ES, Blum JL, Cristea S, Sicinski P, Fan R, Long HW, Sukumar S, Park SY, Garber JE, Bissell M, Yao J, Polyak K.

Nat Commun. 2019 Sep 13;10(1):4182. doi: 10.1038/s41467-019-12125-5.

2.

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.

Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Min Hui Kim E, McDonnell CH 3rd, Wagner J, Rowberry R, Freeman GJ, Dillon D, Sorlie T, Coussens LM, Garber JE, Fan R, Bobolis K, Allred DC, Jeong J, Park SY, Michor F, Polyak K.

Cancer Discov. 2017 Oct;7(10):1098-1115. doi: 10.1158/2159-8290.CD-17-0222. Epub 2017 Jun 26.

3.

Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.

Goncalves R, DeSchryver K, Ma C, Tao Y, Hoog J, Cheang M, Crouch E, Dahiya N, Sanati S, Barnes M, Sarian LOZ, Olson J, Allred DC, Ellis MJ.

Breast Cancer Res Treat. 2017 Sep;165(2):355-364. doi: 10.1007/s10549-017-4329-y. Epub 2017 Jun 13.

4.

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA Jr, Allred DC, Hunt K.

J Clin Oncol. 2017 Apr 1;35(10):1061-1069. doi: 10.1200/JCO.2016.69.4406. Epub 2017 Jan 3.

5.

An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.

Luo J, Liu S, Leung S, Gru AA, Tao Y, Hoog J, Ho J, Davies SR, Allred DC, Salavaggione AL, Snider J, Mardis ER, Nielsen TO, Ellis MJ.

J Mol Diagn. 2017 Jan;19(1):147-161. doi: 10.1016/j.jmoldx.2016.09.007.

6.

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.

Kurozumi S, Padilla M, Kurosumi M, Matsumoto H, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Ranger-Moore J, Allred DC, Dennis E, Nitta H.

Breast Cancer Res Treat. 2016 Jul;158(1):99-111. doi: 10.1007/s10549-016-3856-2. Epub 2016 Jun 18.

7.

Timing of adjuvant surgical oophorectomy in the menstrual cycle and disease-free and overall survival in premenopausal women with operable breast cancer.

Love RR, Laudico AV, Van Dinh N, Allred DC, Uy GB, Quang le H, Salvador JD, Siguan SS, Mirasol-Lumague MR, Tung ND, Benjaafar N, Navarro NS Jr, Quy TT, De La Peña AS, Dofitas RB, Bisquera OC Jr, Linh ND, To TV, Young GS, Hade EM, Jarjoura D.

J Natl Cancer Inst. 2015 Mar 19;107(6):djv064. doi: 10.1093/jnci/djv064. Print 2015 Jun.

8.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2013 Nov 1;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984. Epub 2013 Oct 7.

PMID:
24101045
9.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists.

Arch Pathol Lab Med. 2014 Feb;138(2):241-56. doi: 10.5858/arpa.2013-0953-SA. Epub 2013 Oct 7.

10.

Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis.

Chan SR, Rickert CG, Vermi W, Sheehan KC, Arthur C, Allen JA, White JM, Archambault J, Lonardi S, McDevitt TM, Bhattacharya D, Lorenzi MV, Allred DC, Schreiber RD.

Cell Death Differ. 2014 Feb;21(2):234-46. doi: 10.1038/cdd.2013.116. Epub 2013 Sep 13.

11.

Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion.

Xue B, Krishnamurthy K, Allred DC, Muthuswamy SK.

Nat Cell Biol. 2013 Feb;15(2):189-200. doi: 10.1038/ncb2663. Epub 2012 Dec 23.

12.

FGFR1 amplification and the progression of non-invasive to invasive breast cancer.

Gru AA, Allred DC.

Breast Cancer Res. 2012 Nov 14;14(6):116. doi: 10.1186/bcr3340.

13.

Pathologic outcomes of nonmalignant papillary breast lesions diagnosed at imaging-guided core needle biopsy.

Holley SO, Appleton CM, Farria DM, Reichert VC, Warrick J, Allred DC, Monsees BS.

Radiology. 2012 Nov;265(2):379-84. doi: 10.1148/radiol.12111926. Epub 2012 Sep 5.

PMID:
22952379
14.

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Jul 1;10(7):821-9.

15.

Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer.

Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, Colditz G, Medina D, Allred DC.

Cancer Res. 2012 Sep 1;72(17):4574-86. doi: 10.1158/0008-5472.CAN-12-0636. Epub 2012 Jul 2.

16.

Whole-genome analysis informs breast cancer response to aromatase inhibition.

Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER.

Nature. 2012 Jun 10;486(7403):353-60. doi: 10.1038/nature11143.

17.

Intra-mammary ductal transplantation: a tool to study premalignant progression.

Medina D, Edwards DG, Kittrell F, Lee S, Allred DC.

J Mammary Gland Biol Neoplasia. 2012 Jun;17(2):131-3. doi: 10.1007/s10911-012-9259-z. Epub 2012 Jun 12. Review.

PMID:
22688217
18.

Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, Julian TB, Geyer CE Jr, Costantino JP, Land SR, Wolmark N.

J Clin Oncol. 2012 Apr 20;30(12):1268-73. doi: 10.1200/JCO.2010.34.0141. Epub 2012 Mar 5.

19.

Molecular biomarkers of risk in premalignancy and breast cancer prevention.

Allred DC.

Cancer Prev Res (Phila). 2011 Dec;4(12):1947-52. doi: 10.1158/1940-6207.CAPR-11-0478.

20.

Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model.

Valdez KE, Fan F, Smith W, Allred DC, Medina D, Behbod F.

J Pathol. 2011 Dec;225(4):565-73. doi: 10.1002/path.2969. Epub 2011 Sep 26.

21.

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA.

J Clin Oncol. 2011 Jun 10;29(17):2342-9. doi: 10.1200/JCO.2010.31.6950. Epub 2011 May 9.

22.

Fixation time does not affect expression of HER2/neu.

Goldsmith JD, Allred DC, Beasley MB, Eisen R, Fulton RS, Gown AM, Hammond ME.

Am J Clin Pathol. 2011 Mar;135(3):484; author reply 485. doi: 10.1309/AJCPO1ZG6FERBGZB. No abstract available.

PMID:
21350107
23.

Invasive breast cancer.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Feb;9(2):136-222. No abstract available.

PMID:
21310842
24.

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

LaCroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD, Allred DC, Armstrong R, Cummings SR, Eastell R, Ensrud KE, Goss P, Lee A, Neven P, Reid DM, Curto M, Vukicevic S; PEARL Investigators.

J Natl Cancer Inst. 2010 Nov 17;102(22):1706-15. doi: 10.1093/jnci/djq415. Epub 2010 Nov 4.

PMID:
21051656
25.

Breast cancer: noninvasive and special situations.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff AC.

J Natl Compr Canc Netw. 2010 Oct;8(10):1182-207. No abstract available.

PMID:
20971842
26.

Ductal carcinoma in situ: terminology, classification, and natural history.

Allred DC.

J Natl Cancer Inst Monogr. 2010;2010(41):134-8. doi: 10.1093/jncimonographs/lgq035. Review.

27.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC; American Society of Clinical Oncology; College of American Pathologists.

Arch Pathol Lab Med. 2010 Jul;134(7):e48-72. doi: 10.1043/1543-2165-134.7.e48. Review.

PMID:
20586616
28.

Postmenopausal hormone therapy: an Endocrine Society scientific statement.

Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH; Endocrine Society.

J Clin Endocrinol Metab. 2010 Jul;95(7 Suppl 1):s1-s66. doi: 10.1210/jc.2009-2509. Epub 2010 Jun 21. Review.

29.

PIK3CA mutations in in situ and invasive breast carcinomas.

Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K.

Cancer Res. 2010 Jul 15;70(14):5674-8. doi: 10.1158/0008-5472.CAN-08-2660. Epub 2010 Jun 15.

30.

Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays.

Fitzgibbons PL, Murphy DA, Hammond ME, Allred DC, Valenstein PN.

Arch Pathol Lab Med. 2010 Jun;134(6):930-5. doi: 10.1043/1543-2165-134.6.930.

PMID:
20524870
31.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC.

Arch Pathol Lab Med. 2010 Jun;134(6):907-22. doi: 10.1043/1543-2165-134.6.907. Erratum in: Arch Pathol Lab Med. 2010 Aug;134(8):1101.

32.

Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.

Allred DC.

Mod Pathol. 2010 May;23 Suppl 2:S52-9. doi: 10.1038/modpathol.2010.55. Review.

33.

Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone.

Allred DC.

J Natl Cancer Inst. 2010 May 5;102(9):585-7. doi: 10.1093/jnci/djq118. Epub 2010 Apr 28. No abstract available.

PMID:
20427432
34.

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC.

J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529. Epub 2010 Apr 19. Review. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.

35.

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Breast Cancer Intergroup of North America.

Lancet Oncol. 2010 Jan;11(1):55-65. doi: 10.1016/S1470-2045(09)70314-6. Epub 2009 Dec 10.

36.

NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.

Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC.

J Natl Compr Canc Netw. 2009 Sep;7 Suppl 6:S1-S21; quiz S22-3. Review.

PMID:
19755043
37.

Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.

Migliaccio I, Wu MF, Gutierrez C, Malorni L, Mohsin SK, Allred DC, Hilsenbeck SG, Osborne CK, Weiss H, Lee AV.

Breast Cancer Res Treat. 2010 Oct;123(3):651-60. doi: 10.1007/s10549-009-0632-6. Epub 2009 Nov 19.

38.

An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ.

Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, Young E, Mukhopadhyay P, Yeh HW, Allred DC, Hu M, Polyak K, Rosen JM, Medina D.

Breast Cancer Res. 2009;11(5):R66. doi: 10.1186/bcr2358.

39.

"Dwarf" estrogen receptor in breast cancer and resistance to tamoxifen.

Fowler AM, Santen RJ, Allred DC.

J Clin Oncol. 2009 Jul 20;27(21):3413-5. doi: 10.1200/JCO.2009.21.8776. Epub 2009 Jun 1. No abstract available.

PMID:
19487375
40.

Breast cancer. Clinical practice guidelines in oncology.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC; NCCN Breast Cancer Clinical Practice Guidelines Panel.

J Natl Compr Canc Netw. 2009 Feb;7(2):122-92. Review. No abstract available.

PMID:
19200416
41.

The utility of conventional and molecular pathology in managing breast cancer.

Allred DC.

Breast Cancer Res. 2008;10 Suppl 4:S4. doi: 10.1186/bcr2164. Epub 2008 Dec 18. No abstract available.

42.

Commentary: hormone receptor testing in breast cancer: a distress signal from Canada.

Allred DC.

Oncologist. 2008 Nov;13(11):1134-6. doi: 10.1634/theoncologist.2008-0184. Epub 2008 Nov 5. No abstract available.

43.

The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer.

Nolan ME, Aranda V, Lee S, Lakshmi B, Basu S, Allred DC, Muthuswamy SK.

Cancer Res. 2008 Oct 15;68(20):8201-9. doi: 10.1158/0008-5472.CAN-07-6567.

44.

The relevance of mouse models to understanding the development and progression of human breast cancer.

Allred DC, Medina D.

J Mammary Gland Biol Neoplasia. 2008 Sep;13(3):279-88. doi: 10.1007/s10911-008-9093-5. Epub 2008 Aug 14. Review.

PMID:
18704660
45.

Response and resistance to the endocrine prevention of breast cancer.

Howell A, Bundred NJ, Cuzick J, Allred DC, Clarke R.

Adv Exp Med Biol. 2008;617:201-11. doi: 10.1007/978-0-387-69080-3_19. Review.

PMID:
18497044
46.

Problems and solutions in the evaluation of hormone receptors in breast cancer.

Allred DC.

J Clin Oncol. 2008 May 20;26(15):2433-5. doi: 10.1200/JCO.2007.15.7800. No abstract available.

PMID:
18487563
47.

Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.

Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, O'Connell P, Tsimelzon A, Medina D.

Clin Cancer Res. 2008 Jan 15;14(2):370-8. doi: 10.1158/1078-0432.CCR-07-1127.

48.

Steroid receptor coactivator 2 is required for female fertility and mammary morphogenesis: insights from the mouse, relevance to the human.

Mukherjee A, Amato P, Allred DC, DeMayo FJ, Lydon JP.

Nucl Recept Signal. 2007 Nov 30;5:e011. doi: 10.1621/nrs.05011. Review.

49.

Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy.

Phillips T, Murray G, Wakamiya K, Askaa J, Huang D, Welcher R, Pii K, Allred DC.

Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):325-31.

PMID:
17721279
50.

Alterations of gene expression in the development of early hyperplastic precursors of breast cancer.

Lee S, Medina D, Tsimelzon A, Mohsin SK, Mao S, Wu Y, Allred DC.

Am J Pathol. 2007 Jul;171(1):252-62.

Supplemental Content

Loading ...
Support Center